Our innovative technology platforms and products have led to collaborations with leading pharmaceutical companies. Recent agreements include:

  • Licensing Agreement with Pfizer Inc. on Antibody Drug Conjugates (ADCs) and targeted nanoparticles.
  • Research collaboration with AbbVie.
  • Worldwide Licensing Agreement with Pfizer Inc. for Dekavil, an Investigational Immunoregulatory Therapy for Autoimmune Diseases.
  • Collaboration with Pfizer Inc. in the field of cancer target discovery.
  • Collaboration with Boehringer Ingelheim exploring novel treatment approaches for Acute Myeloid Leukemia.
  • Collaboration, option and license agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop a new class of immunomodulatory therapeutics.

For additional information about partnering opportunities, please contact:

Dr. Filippo Mulinacci, Head of Business Development

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy